PROPHASE LABS INC. - COMMON STOCK
0.5700
19-February-25 16:45:00
15 minutes delayed
Stocks
+0.1310
+29.84%
Today's range
0.4600 - 0.6600
ISIN
N/A
Source
NASDAQ
-
18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
28 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
21 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces New $6 Million Stock Repurchase Program
15 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
13 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
07 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
01 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
22 Feb 2023 08:00:02 By Nasdaq GlobeNewswire
-
16 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
15 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
05 Jan 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
19 Dec 2022 08:30:00 By Nasdaq GlobeNewswire
-
30 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 Nov 2022 08:00:04 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
08 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs to Present at Investor Summit Group’s Q4 Conference
07 Nov 2022 19:12:00 By Nasdaq GlobeNewswire
-
04 Nov 2022 08:00:00 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Collaboration with G42 Healthcare
19 Oct 2022 08:00:02 By Nasdaq GlobeNewswire
-
ProPhase Labs to Present at The ThinkEquity Conference
18 Oct 2022 08:00:01 By Nasdaq GlobeNewswire